Immunic CEO on Q3 highlights, ECTRIMS 2025 and upcoming milestones

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive's Stephen Gunnion about the company’s third-quarter highlights, with a particular focus on the progress of its oral MS treatment, vidofludimus calcium. Dr Vitt noted the company had a strong presence at the 2025 ECTRIMS conference, presenting important new data from several clinical studies. These included results from the phase 2 CALLIPER study, which showed a statistically significant effect on confirmed disability improvement, and promising data in primary progressive MS patients showing a numerical benefit in slowing disability worsening. He also referenced findings from the EMPhASIS phase 2 open-label extension trial. According to Vitt, “144 weeks later, still 92.3% of the patients were free of 12-week confirmed disability worsening,” highlighting the durability of the drug’s effects and its favorable safety and tolerability profile. Discussing the upcoming ENSURE phase 3 trials in relapsing MS, Vitt explained the company is targeting statistically significant results on the primary endpoint of time to first relapse, with topline data expected in 2026. Secondary endpoints aim to confirm the drug’s neuroprotective potential. He also pointed to recently granted US patents, which strengthen commercial protection for vidofludimus calcium in both relapsing and progressive MS, potentially extending exclusivity beyond 2041. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future content. #ImmunicInc #MultipleSclerosis #MSResearch #VidofludimusCalcium #MSAwareness #BiotechNews #ClinicalTrials #ECTRIMS2025 #Neuroprotection #PharmaUpdate